LabCorp Presents Nine Studies, Including Novel Research on Improving Genetic Counseling Quality, at the National Society of G...
September 14 2017 - 3:05PM
Business Wire
LabCorp’s Integrated Genetics Specialty
Laboratory Leverages Decades of Experience in Genetics Research and
Practice to Improve Health and Improve Lives
LabCorp (NYSE: LH), a leading global life sciences company,
announced today that Integrated Genetics, a member of the LabCorp
Specialty Testing Group, is presenting the results of nine studies
relating to prenatal testing, including non-invasive prenatal
testing (NIPT), and genetic counseling at the 36th Annual
Conference of the National Society of Genetic Counselors, held
Sept. 13-16 in Columbus, Ohio. Integrated Genetics also hosted a
symposium addressing key factors in expanded carrier screening,
which can better identify individuals and couples at increased risk
for passing on certain inherited diseases.
“The research we are presenting at this conference reflects the
knowledge and experience gained from hundreds of thousands of
prenatal cases handled over several decades by the specialists and
genetic counselors of LabCorp and Integrated Genetics,” said Gary
M. Huff, CEO of LabCorp Diagnostics. “We are a market leader in
NIPT, women’s health and reproductive genetics, and we have the
industry’s strongest team of genetic counselors to help patients
and physicians understand what those test results mean. The depth
and breadth of our team’s innovative research speak to how
LabCorp’s scientific experience and expertise are helping to
improve the delivery of care and produce better outcomes.”
The research presented by LabCorp includes a novel study by
primary author Denise Cutillo, vice president genetic counseling
services of Integrated Genetics, that focuses on improving the
quality of genetic counseling. The study, “The impact of a quality
improvement program on genetic counseling,” demonstrates how a
genetic counseling quality improvement program implemented by
Integrated Genetics measurably benefitted patient care. Reflecting
an analysis of over 37,000 patients who received reproductive
genetic counseling from Integrated Genetics over a one-year period,
the study showed that targeted training and tools, including
simple-to-follow checklists, helped both new and experienced
genetic counselors follow current standards of care in the rapidly
changing field of reproductive genetics, providing patients and
their physicians with the most up-to-date information to help guide
care decisions. The program’s focus on patient care promotes
excellence in the delivery of personalized genetic risk assessment
and standardized patient care in a national program that supports
tens of thousands of patients annually.
Poster Sessions
Including the Cutillo study, LabCorp and Integrated Genetics are
presenting nine posters at the conference:
- “The many faces of monosomy X:
Unexpected outcomes of monosomy X NIPT results,” by lead author
Samantha Caldwell, M.S.; licensed certified genetic counselor;
clinical laboratory liaison, Integrated Genetics;
- “The complex side of NIPT fetal sex
discrepancies revealed … Karyotype party tricks,” by lead author
Jenna Wardrop, M.S.; licensed certified genetic counselor; lead
clinical laboratory liaison, Integrated Genetics;
- “Genome wide cfDNA: Emerging data
trends in 28K clinical samples,” by lead author Theresa Boomer,
M.S.; licensed certified genetic counselor; senior clinical
laboratory liaison, Integrated Genetics;
- “Full gene sequencing as a follow-up to
carrier screening: Utilization and outcomes,” by lead author
Shannon Doyle, M.S.; licensed certified genetic counselor; genetic
coordinator, Integrated Genetics;
- “Esoteric aneuploidies and genome-wide
cell-free DNA,” by lead author Erica Soster, M.S.; licensed
certified genetic counselor; medial science liaison, medical
affairs, Integrated Genetics;
- “Prenatal diagnosis of a 21q
microduplication after positive NIPT result for trisomy 21: A case
report,” by lead author Lauren Petrarca, M.S.; certified genetic
counselor; senior genetic counselor, Integrated Genetics;
- “Evolving trend in patient
decision-making on non-invasive screening versus invasive testing
following a prenatal diagnosis of ultrasound anomaly,” by lead
author Jillian Carroll, M.S., M.A.; certified genetic counselor;
senior genetic counselor, Integrated Genetics;
- “The impact of a quality improvement
program on genetic counseling,” by Denise Cutillo, M.S.; licensed
certified genetic counselor; vice president, genetic counseling
services, Integrated Genetics; and
- “Maternal serum screen positive results
- What do patients elect next?” by lead author Kristi Fissell,
M.S.; certified genetic counselor; director, genetic counseling
services, Integrated Genetics.
Beginning Sept. 19, copies of the posters will be available,
free of charge, at
www.IntegratedGenetics/WhyIntegratedGenetics/PostersandPublications.
Symposium
LabCorp also presented a symposium titled “Key Factors in
Quality Expanded Carrier Screening: From Parental Testing to
Prenatal Diagnosis.” The discussion focused on how to identify the
most significant factors in quality expanded carrier screening,
including clinically relevant tests, technology considerations,
data analysis and interpretation, and prenatal diagnosis. It also
included clinical scenarios in carrier screening to help
participants better understand the optimal quality considerations
to best support patient care.
Presenters for the symposium were:
- Ruth A. Heim; Ph.D.; fellow, American
College of Medical Genetics and Genomics; clinical laboratory
director, Integrated Genetics;
- Ellen Schlenker; M.S.; licensed
certified genetic counselor; regional manager of genetic
counseling, Integrated Genetics; and
- Brittany Dyr; M.S.; certified genetic
counselor; medical science liaison, Integrated Genetics.
Additional information about the conference is available at
http://www.nsgc.org/conference.
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global
life sciences company that is deeply integrated in guiding patient
care, providing comprehensive clinical laboratory and end-to-end
drug development services. With a mission to improve health and
improve lives, LabCorp delivers world-class diagnostic solutions,
brings innovative medicines to patients faster and uses technology
to improve the delivery of care. LabCorp reported net revenues of
nearly $9.5 billion for 2016. To learn more about LabCorp, visit
www.labcorp.com, and to learn more about Covance Drug Development,
visit www.covance.com.
This press release contains forward-looking statements about the
Company’s future operations. Each of the forward-looking statements
is subject to change based on various important factors, including
without limitation, competitive actions in the marketplace, and
adverse actions of governmental and other third-party payers.
Actual results could differ materially from those suggested by
these forward-looking statements. The Company has no obligation to
provide any updates to these forward-looking statements even if its
expectations change. Further information on potential factors that
could affect operating and financial results is included in the
Company’s Form 10-K for the year ended December 31, 2016, and
subsequent Forms 10-Q, including in each case under the heading
risk factors, and in the Company’s other filings with the SEC. The
information in this press release should be read in conjunction
with a review of the Company’s filings with the SEC including the
information in the Company’s Form 10-K for the year ended December
31, 2016, and subsequent Forms 10-Q, under the heading MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170914006295/en/
LabCorpMedia Contact:Donald Von Hagen,
336-436-8263orInvestor Contact:Scott Frommer,
336-436-5076
Labcorp (NYSE:LH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Labcorp (NYSE:LH)
Historical Stock Chart
From Sep 2023 to Sep 2024